ClinicalTrials.gg
RecruitingNCT07881458AMPLIFY-2Updated Nov 4, 2026

A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes

A Phase 3 interventional study of eloralintide and tirzepatide and Tirzepatide in Obesity, Overweight and Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Recruiting at 75 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 4, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing eloralintide in Obesity — 14 open to participants now, 15 under way, 8 of them phase 3. eloralintide · Obesity.

Planned enrollment
6th of 22
1,000 · median 315
Started
2026
with 11 others
Phase 3
8 of 22
8 open now
Primary completion
2029-10
later than 12 of 14 live
Registered
20th of 22
by date
Lead sponsor
22 of 22
Eli Lilly and Company

Among the 22 studies testing eloralintide in Obesity, this one is the 6th largest by planned enrollment, is one of 12 that started in 2026, is one of 8 in phase 3, reaches primary completion later than 12 of the 14 other live ones, and was the 20th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

14 of the 22 studies testing eloralintide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About eloralintide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing eloralintide in Obesity, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared to tirzepatide for body weight reduction in participants with obesity or overweight and type 2 diabetes.

Participation in the study will last about 2 years.

03

Conditions studied

  • Obesity
  • Overweight
  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have type 2 diabetes
  • Have a stable self-reported body weight (\<5% body weight change) for 90 days prior to screening
  • Have a of ≥27 kg/m2 at screening
  • Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight

Exclusion criteria

Exclusion Criteria:

  • Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening)
  • Have a prior or planned endoscopic procedure and/or device-based therapy for obesity and/or type 2 diabetes (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
  • Have type 1 diabetes
  • Have taken any of the following within 90 days prior to screening

    • medications with direct amylin, glucagon-like peptide-1 (GLP-1) or glucagon-dependent insulinotropic polypeptide (GIP) receptor activity, including compounded therapies
    • dipeptidyl peptidase 4 (DPP-4) inhibitors, and
    • insulin
  • Have had within 90 days prior to screening:

    • heart attack
    • stroke
    • coronary artery revascularization
    • unstable angina, or
    • hospitalization due to congestive heart failure
  • Have a history or diagnosis of Functional Classification Class IV congestive heart failure
  • Have taken medications or alternative remedies intended for weight loss within 90 days of screening
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    EloraTZP

    Participants will receive EloraTZP subcutaneously (SC)

    Drug: eloralintide and tirzepatide

  • Experimental
    Tirzepatide

    Participants will receive tirzepatide SC

    Drug: Tirzepatide

Interventions

06

What researchers measure

Primary outcomes

  1. Percent Change from Baseline in Body Weight

    Time frame: Baseline, Week 100

Secondary outcomes

  1. Change from Baseline in Waist Circumference

    Time frame: Baseline, Week 100

  2. Change from Baseline in Hemoglobin A1c (HbA1c)

    Time frame: Baseline, Week 100

  3. Change from Baseline in Systolic Blood Pressure

    Time frame: Baseline, Week 100

  4. Percent Change from Baseline in High-Sensitivity C-Reactive Protein (hsCRP)

    Time frame: Baseline, Week 100

  5. Percent Change from Baseline in Total Body Fat Mass

    Time frame: Baseline, Week 100

  6. Change from Baseline in Body Mass Index (BMI)

    Time frame: Baseline, Week 100

  7. Change from Baseline in Fasting Glucose

    Time frame: Baseline, Week 100

  8. Percentage of Participants who Achieve a Composite of Body Weight Reduction ≥ 15% and HbA1c <6.5%

    Time frame: Week 100

  9. Percent Change from Baseline in Total Cholesterol

    Time frame: Baseline, Week 100

  10. Percent Change from Baseline in Fasting Insulin

    Time frame: Baseline, Week 100

  11. Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)

    Time frame: Baseline, Week 100

  12. Change from Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite CT) Total Score

    Time frame: Baseline, Week 100

  13. Change from Baseline in EQ-5D-5L Score

    Time frame: Baseline, Week 100

  14. Change from Baseline in Eating Behaviors and Attitudes Questionnaire (EBAQ) Score

    Time frame: Baseline, Week 100

  15. Achievement of Improved Categorical Shift in Patient Global Impression of Severity (PGIS) Physical Function Weight

    Time frame: Baseline, Week 100

  16. Percentage of Participants with a Change in Medication Use

    Time frame: Baseline, Week 100

  17. Overall Functional Assessment of Chronic Illness Therapy, Item GP5 (FACT-GP5) Score

    Time frame: Week 100

  18. Pharmacokinetics (PK): Maximum Concentration of Eloralintide at Steady State (Cmax,ss)

    Time frame: Baseline through Week 100

  19. PK: Area Under the Concentration Versus Time Curve of Eloralintide for One Dosing Interval at Steady State (AUC(0-ᴛ)ss)

    Time frame: Baseline through Week 100

  20. PK: Maximum Concentration of Tirzepatide at Steady State (Cmax,ss)

    Time frame: Baseline through Week 100

  21. PK: Area Under the Concentration Versus Time Curve of Tirzepatide for One Dosing Interval at Steady State (AUC(0-ᴛ)ss)

    Time frame: Baseline through Week 100

07

Study locations

1 of 75 sites recruiting
  • Tucson Clinical Research Institute
    Tucson, Arizona 85712, United States
    Not yet recruiting
    • Girish Karamchandani · Principal investigator
  • Pacific Clinical Studies Inc.
    Los Alamitos, California 90720, United States
    Not yet recruiting
    • · Contact562-598-0600 ext 205
    • Etsegenet Ayele · Principal investigator
  • Los Angeles Institute for Metabolic Research
    Los Angeles, California 90015, United States
    Recruiting
    • · Contact213-373-8380
    • Juan Frias · Principal investigator
  • University of Colorado Anschutz Medical Campus
    Aurora, Colorado 80045, United States
    Not yet recruiting
    • · Contact303-724-9005
    • Daniel Bessesen · Principal investigator
  • American Research Centers of Florida
    Pembroke Pines, Florida 33027, United States
    Not yet recruiting
    • · Contact9542373799
    • Nora Bassam Khoury · Principal investigator
  • Encore Medical Research - Weston
    Weston, Florida 33331, United States
    Not yet recruiting
    • · Contact954-777-8827
    • Sandro Bacchelli · Principal investigator
  • Care Access - Dalton - Clinical Trials Center by Walmart & Care Access
    Dalton, Georgia 30720, United States
    Not yet recruiting
    • · Contact877-791-0656
    • Chukwukanene Ofiaeli · Principal investigator
  • Pacific Diabetes & Endocrine Center
    Honolulu, Hawaii 96817, United States
    Not yet recruiting
    • · Contact8085260303
    • ALAN PARSA · Principal investigator
  • DM Clinical Research - Indianapolis
    Indianapolis, Indiana 46254, United States
    Not yet recruiting
    • · Contact463-271-3050
    • Brandon Essink · Principal investigator
  • Care Access - Eunice
    Eunice, Louisiana 70535, United States
    Not yet recruiting
    • · Contact3374578841
    • Randall Miller · Principal investigator
  • Tandem Clinical Research
    Marrero, Louisiana 70072, United States
    Not yet recruiting
    • · Contact504-934-8424
    • Adil Fatakia · Principal investigator
  • Care Access - St. Louis
    St Louis, Missouri 63131, United States
    Not yet recruiting
    • Anthony Margherita · Principal investigator
  • IMA Clinical Research Warren
    Warren Township, New Jersey 07059, United States
    Not yet recruiting
    • Samar Hameed · Principal investigator
  • NYC Research
    New York, New York 10016, United States
    Not yet recruiting
    • · Contact516-574-9232
    • Anastasios Manessis · Principal investigator
  • IMA Clinical Research NYC Midtown
    New York, New York 10036, United States
    Not yet recruiting
    • Eli Shalenberg · Principal investigator
  • IMA Clinical Research Austin
    Austin, Texas 78745, United States
    Not yet recruiting
    • · Contact5126490082
    • Nomita Kim · Principal investigator
  • Diabetes and Thyroid Center of Ft. Worth
    Fort Worth, Texas 76132, United States
    Not yet recruiting
    • · Contact8172630007
    • Anjanette Tan · Principal investigator
  • Juno Research
    Houston, Texas 77040, United States
    Not yet recruiting
    • · Contact713-779-5494
    • Damaris Vega · Principal investigator
  • Care Access - Houston - Clinical Trials Center by Walmart & Care Access
    Houston, Texas 77082, United States
    Not yet recruiting
    • · Contact877-791-0656
    • Ali Bajwa · Principal investigator
  • ERA Health Research-Texas
    Midland, Texas 79707, United States
    Not yet recruiting
    • · Contact4325287555
    • Sapna Chilka · Principal investigator
  • Texas Valley Clinical Research (TVCR) - Mission
    Mission, Texas 78572, United States
    Not yet recruiting
    • Alejandro Gonzalez Campos · Principal investigator
  • IMA Clinical Research San Antonio
    San Antonio, Texas 78229, United States
    Not yet recruiting
    • · Contact210-692-7157
    • Lisa Blair · Principal investigator
  • Care Access - Tyler - Clinical Trials Center by Walmart & Care Access
    Tyler, Texas 75704, United States
    Not yet recruiting
    • · Contact877-791-0656
    • Alphonse Ekole · Principal investigator
  • Washington Center for Weight Management and Research
    Arlington, Virginia 22206, United States
    Not yet recruiting
    • · Contact7038070037
    • Domenica Rubino · Principal investigator
  • Eastside Research Associates
    Redmond, Washington 98052, United States
    Not yet recruiting
    • · Contact(425) 869-6828
    • Christopher Price · Principal investigator
  • Centro de Pesquisa Sao Lucas
    Campinas, 13060-803, Brazil
    Not yet recruiting
    • · Contact55 19 3343-8688
    • Danilo Villagelin Neto · Principal investigator
  • Cline Research Center
    Curitiba, 80030-480, Brazil
    Not yet recruiting
    • · Contact+554130273930
    • Silmara Leite · Principal investigator
  • Núcleo de Pesquisa Clínica do Rio Grande do Sul
    Porto Alegre, 90430-001, Brazil
    Not yet recruiting
    • · Contact555137796400
    • Luis Henrique Canani · Principal investigator
  • IBPClin - Instituto Brasil de Pesquisa Clínica
    Rio de Janeiro, 20241-180, Brazil
    Not yet recruiting
    • · Contact552125277979
    • Renata Alexandra Pinheiro · Principal investigator
  • CPCLIN
    São Paulo, 01228-200, Brazil
    Not yet recruiting
    • · Contact551126303777
    • Denise Franco · Principal investigator
  • CEPIC - Centro Paulista de Investigação Clínica
    São Paulo, 04266-010, Brazil
    Not yet recruiting
    • · Contact551122713450
    • Breno Balabem Alves · Principal investigator
  • The Second Hospital of Jilin University
    Changchun, 130041, China
    Not yet recruiting
    • Hanqing Cai · Principal investigator
  • Jinan Central Hospital
    Jinan, 250013, China
    Not yet recruiting
    • Nianrong Mi · Principal investigator
  • The First Affiliated Hospital of Henan University of Science &Technology
    Luoyang Shi, 471023, China
    Not yet recruiting
    • · Contact13653880139
    • Hongwei Jiang · Principal investigator
  • The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, 210011, China
    Not yet recruiting
    • · Contact18951762960
    • Yibing Lu · Principal investigator
  • Ningbo First Hospital
    Ningbo, 315010, China
    Not yet recruiting
    • · Contact13757426626
    • Li Li · Principal investigator
  • The First Hospital of Hebei Medical University
    Shijiazhuang, 50000, China
    Not yet recruiting
    • Huijuan Ma · Principal investigator
  • Tianjin Medical University Zhu Xianyi Memorial Hospital
    Tianjin, 300400, China
    Not yet recruiting
    • Liming Chen · Principal investigator
  • StudyPoint Duisburg
    Duisburg, 47269, Germany
    Not yet recruiting
    • · Contact+491725448897
    • Matthias Kuenster · Principal investigator
  • Diabetes Zentrum Wilhelmsburg
    Hamburg, 21109, Germany
    Not yet recruiting
    • · Contact0049407541703
    • Peter Witzel · Principal investigator
  • Institut für Diabetesforschung GmbH Münster
    Münster, 48145, Germany
    Not yet recruiting
    • · Contact0049 251 935 2321
    • Ludger Rose · Principal investigator
  • Schwerpunktpraxis für Diabetes und Ernährungsmedizin Dr. med. Winfried Keuthage
    Münster, 48153, Germany
    Not yet recruiting
    • · Contact02517775888
    • Winfried Keuthage · Principal investigator
  • FutureMeds Offenbach
    Offenbach, 63065, Germany
    Not yet recruiting
    • · Contact0049 69 247433849
    • Christel Contzen · Principal investigator
  • RED-Institut GmbH
    Oldenburg, 23758, Germany
    Not yet recruiting
    • · Contact0049436150630128
    • Thomas Schaum · Principal investigator
  • Medical Corporation Chiseikai Tokyo Center Clinic
    Chūōku, 103-0027, Japan
    Not yet recruiting
    • · Contact81120023812
    • Hirotaka Nagashima · Principal investigator
  • Tokyo Asbo Clinic
    Chūōku, 104-0031, Japan
    Not yet recruiting
    • · Contact81120023812
    • Akiyoshi Uchiyama · Principal investigator
  • Chiba Saiseikai Narashino hospital
    Narashino, 275-8580, Japan
    Not yet recruiting
    • · Contact81120023812
    • Takuya Minamizuka · Principal investigator
  • Soka Sugiura Internal Medicine Clinic
    Sōka, 340-0015, Japan
    Not yet recruiting
    • · Contact81120023812
    • Tatsushi Sugiura · Principal investigator
  • Tsuchiura Beryl Clinic
    Tsuchiura, 300-0062, Japan
    Not yet recruiting
    • · Contact81120023812
    • Kota Yamada · Principal investigator
  • Latin Clinical Trial Center
    San Juan, 00909, Puerto Rico
    Not yet recruiting
    • · Contact7879859911
    • Alex Gonzalez-Bossolo · Principal investigator
  • CMI Cardiologie - Dr. Mercea Corina Delia
    Baia Mare, 430124, Romania
    Not yet recruiting
    • · Contact0040724044581
    • Mihaela Mociran · Principal investigator
  • C.M.D.T.A. Neomed
    Brasov, 500283, Romania
    Not yet recruiting
    • · Contact0040762249010
    • Liliana Marin · Principal investigator
  • Geea Medical Easy Diet
    Bucharest, 010627, Romania
    Not yet recruiting
    • · Contact40314288633
    • Georgeta Vacaru · Principal investigator
  • Centrul Medical NutriLife
    Bucharest, 013764, Romania
    Not yet recruiting
    • · Contact0040212323445
    • Marlena Pascu · Principal investigator
  • Futuremeds - București
    Bucharest, 031441, Romania
    Not yet recruiting
    • · Contact+40 723 680 497
    • Oana-Andreea Parliteanu · Principal investigator
  • Futuremeds - Craiova 2
    Craiova, 200528, Romania
    Not yet recruiting
    • · Contact40763670811
    • Ionela Mihaela Vladu · Principal investigator
  • Futuremeds - Galați
    Galați, 800183, Romania
    Not yet recruiting
    • · Contact0040724405355
    • Cristina-Victoria Mistodie · Principal investigator
  • Gama Diamed
    Mangalia, 905500, Romania
    Not yet recruiting
    • · Contact0040241740581
    • Amalia Thury-Burileanu · Principal investigator
  • Diabdana
    Oradea, 410147, Romania
    Not yet recruiting
    • · Contact004 0722 480 224
    • Dana Cosma · Principal investigator
  • Clinica Korall
    Satu Mare, 440055, Romania
    Not yet recruiting
    • · Contact40746013882
    • Adriana Filimon · Principal investigator
  • Korea University Ansan Hospital
    Ansan-si, 15355, South Korea
    Not yet recruiting
    • · Contact82314124274
    • NANHEE KIM · Principal investigator
  • Chosun University Hospital
    Gwangju, 61453, South Korea
    Not yet recruiting
    • Sang Yong Kim · Principal investigator
  • Seoul National University Bundang Hospital
    Seongnam, 13620, South Korea
    Not yet recruiting
    • Soo Lim · Principal investigator
  • Nowon Eulji Medical Center, Eulji University
    Seoul, 01830, South Korea
    Not yet recruiting
    • · Contact1093908214
    • kyungwan Min · Principal investigator
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, South Korea
    Not yet recruiting
    • Byung Wan Lee · Principal investigator
  • CHUAC-Complejo Hospitalario Universitario A Coruña
    A Coruña, 15006, Spain
    Not yet recruiting
    • · Contact655624017
    • Alfonso Soto Gonzalez · Principal investigator
  • Hospital Universitario de La Ribera
    Alzira, 46600, Spain
    Not yet recruiting
    • · Contact34657845358
    • carmen fajardo · Principal investigator
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
    Not yet recruiting
    • · Contact34697817352
    • ANDREEA CIUDIN · Principal investigator
  • Hospital Clínic de Barcelona
    Barcelona, 08036, Spain
    Not yet recruiting
    • · Contact34660560288
    • Ana de Hollanda · Principal investigator
  • Complejo Hospitalario Universitario de Ferrol (CHUF)- Hospital Naval
    Ferrol, 15405, Spain
    Not yet recruiting
    • Alma Maria Prieto tenreiro · Principal investigator
  • Hospital Vithas La Salud
    Granada, 18008, Spain
    Not yet recruiting
    • · Contact658011529
    • Cristobal Morales Portillo · Principal investigator
  • H.R.U Málaga - Hospital Civil
    Málaga, 29009, Spain
    Not yet recruiting
    • · Contact951290305
    • GABRIEL OLVEIRA · Principal investigator
  • Hospital Universitario Virgen Del Rocio
    Seville, 41013, Spain
    Not yet recruiting
    • · Contact955012000
    • Virginia Bellido · Principal investigator
  • Vithas Hospital Sevilla
    Seville, 41950, Spain
    Not yet recruiting
    • · Contact658011529
    • Cristobal Morales Portillo · Principal investigator
  • Hsinchu Mackay Memorial Hospital
    Hsinchu, 300, Taiwan
    Not yet recruiting
    • Lawrence Liu · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Oct 2029, 36 months after the start.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 36 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

Start moved once since we started tracking on Sep 25, 2026: Nov 2026 → Oct 2026, on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2026
First posted
Oct 19, 2026
StartActual
Oct 16, 2026was Nov 2026
Primary completionEst.
Oct 2029
CompletionEst.
Nov 2029
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 4, 2026
Sites
75 sites changed recruiting status (74 now not yet recruiting, 1 now recruiting)
Show 75 sites
  • Tucson Clinical Research Institute · Tucson, United Statesno status→Not yet recruiting
  • Pacific Clinical Studies Inc. · Los Alamitos, United Statesno status→Not yet recruiting
  • Los Angeles Institute for Metabolic Research · Los Angeles, United Statesno status→Recruiting
  • University of Colorado Anschutz Medical Campus · Aurora, United Statesno status→Not yet recruiting
  • American Research Centers of Florida · Pembroke Pines, United Statesno status→Not yet recruiting
  • Encore Medical Research - Weston · Weston, United Statesno status→Not yet recruiting
  • Care Access - Dalton - Clinical Trials Center by Walmart & Care Access · Dalton, United Statesno status→Not yet recruiting
  • Pacific Diabetes & Endocrine Center · Honolulu, United Statesno status→Not yet recruiting
  • DM Clinical Research - Indianapolis · Indianapolis, United Statesno status→Not yet recruiting
  • Care Access - Eunice · Eunice, United Statesno status→Not yet recruiting
  • Tandem Clinical Research · Marrero, United Statesno status→Not yet recruiting
  • Care Access - St. Louis · St Louis, United Statesno status→Not yet recruiting
  • IMA Clinical Research Warren · Warren Township, United Statesno status→Not yet recruiting
  • NYC Research · New York, United Statesno status→Not yet recruiting
  • IMA Clinical Research NYC Midtown · New York, United Statesno status→Not yet recruiting
  • IMA Clinical Research Austin · Austin, United Statesno status→Not yet recruiting
  • Diabetes and Thyroid Center of Ft. Worth · Fort Worth, United Statesno status→Not yet recruiting
  • Juno Research · Houston, United Statesno status→Not yet recruiting
  • Care Access - Houston - Clinical Trials Center by Walmart & Care Access · Houston, United Statesno status→Not yet recruiting
  • ERA Health Research-Texas · Midland, United Statesno status→Not yet recruiting
  • Texas Valley Clinical Research (TVCR) - Mission · Mission, United Statesno status→Not yet recruiting
  • IMA Clinical Research San Antonio · San Antonio, United Statesno status→Not yet recruiting
  • Care Access - Tyler - Clinical Trials Center by Walmart & Care Access · Tyler, United Statesno status→Not yet recruiting
  • Washington Center for Weight Management and Research · Arlington, United Statesno status→Not yet recruiting
  • Eastside Research Associates · Redmond, United Statesno status→Not yet recruiting
  • Centro de Pesquisa Sao Lucas · Campinas, Brazilno status→Not yet recruiting
  • Cline Research Center · Curitiba, Brazilno status→Not yet recruiting
  • Núcleo de Pesquisa Clínica do Rio Grande do Sul · Porto Alegre, Brazilno status→Not yet recruiting
  • IBPClin - Instituto Brasil de Pesquisa Clínica · Rio de Janeiro, Brazilno status→Not yet recruiting
  • CPCLIN · São Paulo, Brazilno status→Not yet recruiting
  • …and 45 more on the registry record
Nov 4, 2026
Start date
Nov 2026→Oct 16, 2026 (actual)
Nov 4, 2026
Registered
First appeared on the registry
Oct 19, 2026
Show all 3 updates
  1. Nov 4, 2026
    Not yet recruiting→Recruiting
    75 sites changed recruiting status (74 now not yet recruiting, 1 now recruiting)
    Show 75 sites
    • Tucson Clinical Research Institute · Tucson, United Statesno status→Not yet recruiting
    • Pacific Clinical Studies Inc. · Los Alamitos, United Statesno status→Not yet recruiting
    • Los Angeles Institute for Metabolic Research · Los Angeles, United Statesno status→Recruiting
    • University of Colorado Anschutz Medical Campus · Aurora, United Statesno status→Not yet recruiting
    • American Research Centers of Florida · Pembroke Pines, United Statesno status→Not yet recruiting
    • Encore Medical Research - Weston · Weston, United Statesno status→Not yet recruiting
    • Care Access - Dalton - Clinical Trials Center by Walmart & Care Access · Dalton, United Statesno status→Not yet recruiting
    • Pacific Diabetes & Endocrine Center · Honolulu, United Statesno status→Not yet recruiting
    • DM Clinical Research - Indianapolis · Indianapolis, United Statesno status→Not yet recruiting
    • Care Access - Eunice · Eunice, United Statesno status→Not yet recruiting
    • Tandem Clinical Research · Marrero, United Statesno status→Not yet recruiting
    • Care Access - St. Louis · St Louis, United Statesno status→Not yet recruiting
    • IMA Clinical Research Warren · Warren Township, United Statesno status→Not yet recruiting
    • NYC Research · New York, United Statesno status→Not yet recruiting
    • IMA Clinical Research NYC Midtown · New York, United Statesno status→Not yet recruiting
    • IMA Clinical Research Austin · Austin, United Statesno status→Not yet recruiting
    • Diabetes and Thyroid Center of Ft. Worth · Fort Worth, United Statesno status→Not yet recruiting
    • Juno Research · Houston, United Statesno status→Not yet recruiting
    • Care Access - Houston - Clinical Trials Center by Walmart & Care Access · Houston, United Statesno status→Not yet recruiting
    • ERA Health Research-Texas · Midland, United Statesno status→Not yet recruiting
    • Texas Valley Clinical Research (TVCR) - Mission · Mission, United Statesno status→Not yet recruiting
    • IMA Clinical Research San Antonio · San Antonio, United Statesno status→Not yet recruiting
    • Care Access - Tyler - Clinical Trials Center by Walmart & Care Access · Tyler, United Statesno status→Not yet recruiting
    • Washington Center for Weight Management and Research · Arlington, United Statesno status→Not yet recruiting
    • Eastside Research Associates · Redmond, United Statesno status→Not yet recruiting
    • Centro de Pesquisa Sao Lucas · Campinas, Brazilno status→Not yet recruiting
    • Cline Research Center · Curitiba, Brazilno status→Not yet recruiting
    • Núcleo de Pesquisa Clínica do Rio Grande do Sul · Porto Alegre, Brazilno status→Not yet recruiting
    • IBPClin - Instituto Brasil de Pesquisa Clínica · Rio de Janeiro, Brazilno status→Not yet recruiting
    • CPCLIN · São Paulo, Brazilno status→Not yet recruiting
    • …and 45 more on the registry record
    Start date Nov 2026→Oct 16, 2026 (now actual)
    + 1 other change: verification date
  2. Nov 3, 2026
    Minor edits only
    + 1 other change: references
  3. Oct 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07881458
Responsible party
Sponsor
First posted
Oct 19, 2026
Start date
Oct 16, 2026
Primary completion
Oct 2029 (estimated)
Completion
Nov 2029 (estimated)
Last update
Nov 4, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Eloralintide · Tirzepatide

Start the discussion